STAAR Surgical Operating Income 2012-2026 | STAA
STAAR Surgical operating income from 2012 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
STAAR Surgical Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $-92 |
| 2024 | $-13 |
| 2023 | $28 |
| 2022 | $44 |
| 2021 | $33 |
| 2020 | $7 |
| 2019 | $12 |
| 2018 | $7 |
| 2017 | $-4 |
| 2016 | $-13 |
| 2015 | $-5 |
| 2014 | $-8 |
| 2013 | $1 |
| 2012 | $-1 |
| 2011 | $3 |
|
STAAR Surgical Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $10 |
| 2026-03-31 | $8 |
| 2025-12-31 | $-23 |
| 2025-09-30 | $18 |
| 2025-06-30 | $-30 |
| 2025-03-31 | $-57 |
| 2024-12-31 | $-28 |
| 2024-09-30 | $6 |
| 2024-06-30 | $12 |
| 2024-03-31 | $-2 |
| 2023-12-31 | $10 |
| 2023-09-30 | $6 |
| 2023-06-30 | $9 |
| 2023-03-31 | $3 |
| 2022-12-31 | $1 |
| 2022-09-30 | $14 |
| 2022-06-30 | $17 |
| 2022-03-31 | $12 |
| 2021-12-31 | $7 |
| 2021-09-30 | $8 |
| 2021-06-30 | $11 |
| 2021-03-31 | $7 |
| 2020-12-31 | $4 |
| 2020-09-30 | $5 |
| 2020-06-30 | $-1 |
| 2020-03-31 | $-1 |
| 2019-12-31 | $2 |
| 2019-09-30 | $3 |
| 2019-06-30 | $5 |
| 2019-03-31 | $2 |
| 2018-12-31 | $1 |
| 2018-09-30 | $2 |
| 2018-06-30 | $3 |
| 2018-03-31 | $1 |
| 2017-12-31 | $-1 |
| 2017-09-30 | $1 |
| 2017-06-30 | $-1 |
| 2017-03-31 | $-2 |
| 2016-12-31 | $1 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-2 |
| 2016-03-31 | $-10 |
| 2015-12-31 | $0 |
| 2015-09-30 | $-2 |
| 2015-06-30 | $-2 |
| 2015-03-31 | $-2 |
| 2014-12-31 | $-4 |
| 2014-09-30 | $-2 |
| 2014-06-30 | $-1 |
| 2014-03-31 | $-1 |
| 2013-12-31 | $-1 |
| 2013-09-30 | $0 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2012-03-31 | $0 |
| 2011-12-31 | $1 |
| 2011-09-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $1.125B | $0.239B |
| Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $104.880B | 22.04 |
| Cardinal Health (CAH) | United States | $54.109B | 20.66 |
| Becton Dickinson (BDX) | United States | $51.228B | 14.30 |
| West Pharmaceutical Services (WST) | United States | $25.687B | 42.94 |
| Straumann Holding AG (SAUHY) | Switzerland | $18.592B | 0.00 |
| Align Technology (ALGN) | United States | $10.528B | 16.28 |
| Cooper (COO) | United States | $10.130B | 11.56 |
| Henry Schein (HSIC) | United States | $9.754B | 16.48 |
| Merit Medical Systems (MMSI) | United States | $5.146B | 23.48 |
| DENTSPLY SIRONA (XRAY) | United States | $1.960B | 6.87 |
| CONMED (CNMD) | United States | $1.406B | 9.82 |
| Pro-Dex (PDEX) | United States | $0.214B | 19.97 |
| Lifevantage (LFVN) | United States | $0.077B | 11.04 |